Today: Analysts give average Rating of “Buy” to BioCryst Pharmaceuticals Inc. (BCRX)

Today: Analysts give average Rating of “Buy” to BioCryst Pharmaceuticals Inc. (BCRX)

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) has received a consensus rating of “Buy” from the ten ratings firms that are presently covering the firm. Four research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $6.71.

BCRX has been the subject of a number of research reports. FBR & Co restated a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Thursday, September 8th. Zacks Investment Research upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a report on Wednesday, November 9th. HC Wainwright reiterated a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 8th. JPMorgan Chase & Co. reiterated a “hold” rating on shares of BioCryst Pharmaceuticals in a report on Friday, August 5th. Finally, Jefferies Group boosted their price target on shares of BioCryst Pharmaceuticals from $2.00 to $3.00 and gave the stock a “hold” rating in a report on Friday, August 5th.

Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) traded down 3.20% on Monday, hitting $5.75. 231,580 shares of the company traded hands. The stock’s 50-day moving average price is $4.75 and its 200-day moving average price is $3.97. BioCryst Pharmaceuticals has a 12 month low of $1.63 and a 12 month high of $10.98. The company’s market capitalization is $424.11 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, November 7th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.08. The firm earned $7.80 million during the quarter, compared to analysts’ expectations of $5.94 million. BioCryst Pharmaceuticals had a negative net margin of 313.02% and a negative return on equity of 296.19%. The business’s quarterly revenue was down 29.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.20) earnings per share. On average, equities analysts predict that BioCryst Pharmaceuticals will post ($0.92) earnings per share for the current year.

In other news, VP Alane P. Barnes sold 8,357 shares of the company’s stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $4.27, for a total value of $35,684.39. Following the completion of the transaction, the vice president now owns 79,377 shares in the company, valued at approximately $338,939.79. The sale was disclosed in a document filed with the SEC, which is available at this link. 5.80% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of BCRX. Baker BROS. Advisors LP bought a new position in shares of BioCryst Pharmaceuticals during the third quarter valued at about $48,351,000. VHCP Management II LLC boosted its position in shares of BioCryst Pharmaceuticals by 22.0% in the second quarter. VHCP Management II LLC now owns 5,721,142 shares of the biotechnology company’s stock valued at $16,248,000 after buying an additional 1,031,707 shares during the last quarter. RTW Investments LLC boosted its position in shares of BioCryst Pharmaceuticals by 88.0% in the third quarter. RTW Investments LLC now owns 4,204,579 shares of the biotechnology company’s stock valued at $18,542,000 after buying an additional 1,967,513 shares during the last quarter. D. E. Shaw & Co. Inc. boosted its position in shares of BioCryst Pharmaceuticals by 6.7% in the third quarter. D. E. Shaw & Co. Inc. now owns 3,664,867 shares of the biotechnology company’s stock valued at $16,162,000 after buying an additional 231,215 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of BioCryst Pharmaceuticals by 8.7% in the second quarter. Vanguard Group Inc. now owns 3,526,530 shares of the biotechnology company’s stock valued at $10,016,000 after buying an additional 283,202 shares during the last quarter. Institutional investors and hedge funds own 76.72% of the company’s stock.

Related posts

Leave a Comment